CD274 and neoplasm: A consistent result was also observed in the anti-PD-L1 cohort (Mariathasan et al. study), lower m6Sig scores in mUC patients were significantly associated with better clinical outcomes and higher tumor mutational load (anti-PD-L1, HR, 0.66 [95%CI, 0.49 to 0.88], P = 0.004, Figure S7D-F).